EURURO Vol. 71 No. 4

630

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

P. Cornford, J. Bellmunt, M. Bolla, E. Briers, M. De Santis, T. Gross, A.M. Henry, S. Joniau, T.B. Lam,

M.D. Mason, H.G. van der Poel, T.H. van der Kwast, O. Rouvière, T. Wiegel, N. Mottet

This paper summarises the 2016 European Association of Urology (EAU)- European

Society for Radiotherapy & Oncology (ESTRO) - International Society of Geriatric

Oncology (SIOG) Prostate Cancer Guidelines Prostate Cancer Guidelines. Standard

therapy for PSA relapse after radical prostatectomy is salvage radiotherapy at a PSA

of <0.5 ng/ml. Recommendations for treatment of progression after primary

radiotherapy include salvage radical prostatectomy, high-intensity focused

ultrasound (HIFU) and cryosurgical ablation. Androgen deprivation therapy (ADT)

remains the basis for the treatment of metastatic prostate cancer; however,

docetaxel combined with ADT should be considered the standard of care for men

with metastases at first presentation, provided patients are fit. In patients diagnosed

with metastatic castrate-resistant PCa, chemotherapy, new bone-targeting agents

and agents targeting the antiandrogen axis and immunotherapy are treatment

options.

643

Robotic Laparoendoscopic Single-site Retroperitioneal Renal Surgery: Initial Investigation of a Purpose-built Single-port Surgical System

M.J. Maurice, D. Ramirez, J.H. Kaouk

Retropertioneal renal surgery is technically feasible using the third-generation

purpose-built da Vinci SP1098 robotic system for single-site surgery.

648

Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations—A Report of a European School of Oncology Task Force

C.M. Moore, F. Giganti, P. Albertsen, C. Allen, C. Bangma, A. Briganti, P. Carroll, M. Haider,

V. Kasivisvanathan, A. Kirkham, L. Klotz, A. Ouzzane, A.R. Padhani, V. Panebianco, P. Pinto,

P. Puech, A. Rannikko, R. Renard-Penna, K. Touijer, B. Turkbey, H. van Poppel, R. Valdagni,

J. Walz, I. Schoots

The Prostate Cancer Radiological Estimation of Change in Sequential Evaluation

panel recommends that prostate magnetic resonance imaging reports for men on

active surveillance include index lesion size in absolute values at each time point and

an estimation of the likelihood of significant change between baseline and current

images.

656

Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302

J.S. de Bono, M.R. Smith, F. Saad, D.E. Rathkopf, P.F.A. Mulders, E.J. Small, N.D. Shore, K. Fizazi,

P. De Porre, T. Kheoh, J. Li, M.B. Todd, C.J. Ryan, T.W. Flaig

Treatment patterns for metastatic castration-resitant prostate cancer (mCRPC)

have changed substantially. This analysis shows a clinical benefit for subsequent

docetaxel therapy among men with mCRPC whose disease progressed after

treatment with abiraterone acetate. Older patients were less likely to be treated

with subsequent therapy.

665

Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients

W.P. Parker, J.C. Cheville, I. Frank, H.B. Zaid, C.M. Lohse, S.A. Boorjian, B.C. Leibovich,

R.H. Thompson

Updated with longer follow-up and with new cohorts managed with radical or

partial nephrectomy, the tumor stage, size, grade, and necrosis (SSIGN) score

remains a validated prognostic tool to predict cancer-specific survival for patients

with clear cell renal cell carcinoma.

e u r o p e a n u r o l o g y , vo l . 7 1 , n o . 4 , A p r i l 2 0 1 7

Original Articles

Prostate Cancer

Surgery in Motion

Kidney Cancer